Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 6/20 | 0.38 |
| ▸ | RAB9A | P51151 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30106721 | 0.83 | NCF1 (0.46) | NCF1CYP1A2NOS2BACE1CA12 | |
| SCHEMBL1845696 | 0.83 | NCF1 (0.46) | NCF1CYP1A2NOS2BACE1CA12 | |
| Selenium SCHEMBL32667944 | 0.79 | NCF1 (0.43) | NCF1CYP1A2NOS2BACE1CA12 | |
| SCHEMBL9009627 | 0.78 | NCF1 (0.50) | NCF1CYP1A2NOS2BACE1CA12 | |
| SCHEMBL2028207 | 0.76 | S1PR3 (0.47) | NCF1CYP1A2NOS2BACE1CA12 | |
| SCHEMBL20746476 | 0.75 | NCF1 (0.43) | NCF1CYP1A2NOS2BACE1CA12 | |
| SCHEMBL1129147 | 0.74 | NCF1 (0.46) | NCF1CYP1A2NOS2BACE1CA12 | |
| SCHEMBL10020390 | 0.74 | ALDH1A1 (0.53) | NCF1CYP1A2NOS2BACE1CA12 | |
| SCHEMBL827081 | 0.74 | CYP1A2 (0.52) | NCF1CYP1A2NOS2BACE1CA12 | |
| SCHEMBL3294485 | 0.74 | NCF1 (0.46) | NCF1CYP1A2NOS2BACE1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107530344-B | Specific trifluoroethylquinoline analogs for the treatment of sjogren's syndrome | UCB生物制药私人有限公司 | 2020-03-17 | — | — | CN | disclosed |
| CN-107530344-B | Specific trifluoroethylquinoline analogs for the treatment of sjogren's syndrome | UCB生物制药私人有限公司 | 2020-03-17 | — | — | CN | disclosed |
| US-10493074-B2 | Specific trifluoroethyl quinoline analogue for use in the treatment of Sjögren's syndrome | UCB BIOPHARMA SPRL (BE) | 2019-12-03 | — | — | US | disclosed |
| CN-109364071-A | A kind of drug and purposes promoting salivary secretion treatment xerostomia syndrome | 李萍 | 2019-02-22 | — | — | CN | disclosed |
| CN-109152783-A | For treating the specific trifluoroethyl quinoline analog of APDS | UCB生物制药私人有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-109152783-A | For treating the specific trifluoroethyl quinoline analog of APDS | UCB生物制药私人有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-107530344-A | Specific trifluoroethylquinoline analogs for the treatment of Sjogren's syndrome | UCB生物制药私人有限公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107530344-A | Specific trifluoroethylquinoline analogs for the treatment of Sjogren's syndrome | UCB生物制药私人有限公司 | 2018-01-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10493074-B2 | Specific trifluoroethyl quinoline analogue for use in the treatment of Sjögren's syndrome | SSB, SYVN1, QARS1 | NCF1 1292/4885CYP1A2 1464/4885NOS2 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.